Indoco Remedies Receives EU GMP Certification for Goa Plant-I
Indoco Remedies has announced a significant regulatory milestone for its manufacturing operations.
The company’s Goa Plant-I has been granted European Union Good Manufacturing Practice (EU GMP) certification by the Malta Medicines Authority.
The certification confirms that the manufacturing facility complies with the pharmaceutical production standards prescribed under the relevant European Commission Good Manufacturing Practice Directive.
EU GMP certification is an important regulatory requirement for pharmaceutical manufacturers supplying medicines to European markets.
Certification Follows Successful Regulatory Inspection
The certification was issued after the successful completion of a detailed regulatory inspection.
Officials from the Malta Medicines Authority inspected the company’s solid oral dosage manufacturing facility located in Goa.
The inspection was conducted over a six-day period between November 19 and November 24, 2025.
Following the evaluation, the authority concluded that the facility met the required manufacturing standards and subsequently granted the EU GMP certificate.
The certification validates the company’s compliance with internationally recognised pharmaceutical manufacturing practices.
Importance of EU GMP Certification
Good Manufacturing Practice certification plays a critical role in pharmaceutical manufacturing.
EU GMP standards are designed to ensure that medicines are consistently produced and controlled according to established quality requirements.
The certification helps manufacturers demonstrate compliance in areas including:
- Manufacturing processes
- Quality assurance systems
- Documentation practices
- Equipment validation
- Hygiene standards
- Product traceability
Maintaining compliance with these standards is essential for supplying pharmaceutical products to regulated international markets.
Supports Global Pharmaceutical Operations
The latest approval strengthens Indoco Remedies’ international manufacturing capabilities.
With EU GMP certification in place, the Goa manufacturing facility can continue producing pharmaceutical products that require compliance with European regulatory standards.
International certifications also support pharmaceutical companies in maintaining business relationships across regulated healthcare markets where stringent quality requirements are mandatory.
The certification further reinforces the company’s focus on maintaining global quality systems across its manufacturing operations.
Extensive Manufacturing Network
Indoco Remedies operates a diversified manufacturing infrastructure across India.
The company currently has 10 manufacturing facilities, comprising:
- Six Finished Dosage Formulation (FDF) plants
- Four Active Pharmaceutical Ingredient (API) manufacturing facilities
These facilities support the production of a broad portfolio of pharmaceutical products across various therapeutic segments.
The company’s integrated manufacturing network enables formulation development, active ingredient production, and finished product manufacturing under a single operational framework.
Multiple International Regulatory Approvals
Apart from the latest EU GMP certification, Indoco Remedies has received approvals from several international regulatory agencies.
According to the company, its manufacturing facilities have been inspected and approved by authorities including:
- United States Food and Drug Administration (USFDA)
- Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
- Other international pharmaceutical regulators
Regulatory approvals from multiple jurisdictions allow pharmaceutical companies to supply products across various global healthcare markets while meeting local compliance requirements.
Focus on Quality and Regulatory Compliance
Pharmaceutical manufacturing requires continuous compliance with evolving global quality standards.
Regular inspections by international regulatory agencies evaluate manufacturing practices, quality management systems, documentation, validation procedures, and product safety controls.
Receiving certifications from multiple international authorities demonstrates continued adherence to these regulatory frameworks.
The latest EU GMP approval further strengthens Indoco Remedies’ regulatory portfolio.
Indoco Remedies Share Price Performance
Following the announcement, Indoco Remedies shares attracted investor attention during Monday’s trading session.
As of June 29, 2026, at approximately 1:48 PM, the company’s shares were trading at around ₹237.13.
The stock was higher by approximately 2.39% compared with the previous trading session.
Share price movements are influenced by multiple factors, including company announcements, overall market conditions, sector trends, and investor sentiment.
Pharmaceutical Business Continues Global Expansion
Indoco Remedies continues to focus on expanding its presence in regulated international pharmaceutical markets.
Regulatory approvals remain an important component of pharmaceutical exports, particularly in highly regulated regions such as Europe, the United States, and the United Kingdom.
Maintaining certified manufacturing facilities supports long-term participation in these markets while ensuring compliance with international pharmaceutical production standards.
Conclusion
Indoco Remedies has received European Union Good Manufacturing Practice (EU GMP) certification for its Goa Plant-I from the Malta Medicines Authority following a successful inspection completed in November 2025. The certification confirms compliance with European pharmaceutical manufacturing standards and strengthens the company’s international regulatory profile. With a manufacturing network comprising six formulation facilities and four API plants, along with approvals from multiple global regulatory agencies, the company continues to reinforce its quality systems and global pharmaceutical manufacturing capabilities.
Summary
Indoco Remedies witnessed buying interest after announcing that its Goa Plant-I has received European Union Good Manufacturing Practice (EU GMP) certification from the Malta Medicines Authority. The certification follows a successful regulatory inspection of the company’s solid oral dosage manufacturing facility and confirms compliance with European pharmaceutical manufacturing standards. The approval strengthens Indoco Remedies’ international regulatory credentials and supports the continued supply of pharmaceutical products to regulated global markets. The company currently operates multiple formulation and API manufacturing facilities approved by several international regulatory agencies.
Disclaimer:
This article is intended solely for educational and informational purposes. The securities or companies mentioned are provided as examples and should not be considered as recommendations. Nothing contained herein constitutes personal financial advice or investment recommendations. Readers are advised to conduct their own research and consult a qualified financial advisor before making any investment decisions.
Investments in securities markets are subject to market risks. Please read all related documents carefully before investing.
